Australia markets open in 5 hours 28 minutes
  • ALL ORDS

    7,668.90
    +12.30 (+0.16%)
     
  • AUD/USD

    0.7270
    +0.0057 (+0.79%)
     
  • ASX 200

    7,342.40
    +9.90 (+0.14%)
     
  • OIL

    87.05
    +0.09 (+0.10%)
     
  • GOLD

    1,843.20
    0.00 (0.00%)
     
  • BTC-AUD

    59,443.41
    +976.55 (+1.67%)
     
  • CMC Crypto 200

    1,026.88
    +31.62 (+3.18%)
     

Corcept Therapeutics (CORT) Alert: Shareholder Class Action In Part Survives Motion to Dismiss; Should Management be Held Accountable for Investors' Losses? Contact Johnson Fistel

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Corcept Therapeutics, Inc. (NASDAQ: CORT) against certain of its officers and directors. Specifically, a class-action lawsuit pending in the Northern District of California issued an order denying in part the defendants' motion to dismiss in the pending securities class action against Corcept.

According to the lawsuit, defendants throughout the Class Period made false and misleading statements and failed to disclose that: (1) Corcept had improperly paid doctors to promote its drug Korlym; (2) Corcept aggressively promoted Korlym for off-label uses; (3) Corcept's sole specialty pharmacy was a related party; (4) Corcept artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices were reasonably likely to lead to regulatory scrutiny; and (6) as a result, defendants' positive statements about Corcept's business, operations, and prospects were materially misleading and lacked a reasonable basis.

If you are a current, long-term shareholder of Corcept holding shares before August 2, 2017, you may have standing to hold Corcept harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

Additionally, if you have owned Corcept's shares since before August 2, 2017, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

If you have owned Corcept's shares since before August 2, 2017, you can [Click here to join this action]. There is no cost or obligation to you.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting